Aligos Therapeutics Inc [NASDAQ: ALGS] traded at a low on Wednesday, posting a -6.18 loss after which it closed the day’ session at $38.39.
The results of the trading session contributed to over 371894 shares changing hands. Over the past one week, the price volatility of Aligos Therapeutics Inc stands at 11.53% while the volatility over the past one month is 13.58%.
The market cap for ALGS stock reached $137.74 million, with 3.20 million shares outstanding and 2.67 million shares in the current float. Compared to the average trading volume of 418.78K shares, ALGS reached a trading volume of 371894 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Aligos Therapeutics Inc [ALGS]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ALGS shares is $103.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ALGS stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Aligos Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 19, 2024. While these analysts kept the previous recommendation, Piper Sandler raised their target price from $2 to $3. The new note on the price target was released on January 06, 2023, representing the official price target for Aligos Therapeutics Inc stock. Previously, the target price had yet another raise from $2.50 to $3, while Jefferies kept a Buy rating on ALGS stock. On March 23, 2022, analysts decreased their price target for ALGS shares from 15 to 4.
The Average True Range (ATR) for Aligos Therapeutics Inc is set at 4.39, with the Price to Sales ratio for ALGS stock in the period of the last 12 months amounting to 22.96. The Price to Book ratio for the last quarter was 2.55, with the Price to Cash per share for the same quarter was set at 20.91.
How has ALGS stock performed recently?
Aligos Therapeutics Inc [ALGS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.64. With this latest performance, ALGS shares gained by 33.90% in over the last four-week period, additionally plugging by 201.22% over the last 6 months – not to mention a rise of 107.51% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ALGS stock in for the last two-week period is set at 56.78, with the RSI for the last a single of trading hit 50.10, and the three-weeks RSI is set at 60.60 for Aligos Therapeutics Inc [ALGS]. The present Moving Average for the last 50 days of trading for this stock 25.97, while it was recorded at 41.63 for the last single week of trading, and 17.23 for the last 200 days.
Aligos Therapeutics Inc [ALGS]: Deeper insight into the fundamentals
Aligos Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.81 and a Current Ratio set at 3.81.
Insider trade positions for Aligos Therapeutics Inc [ALGS]
There are presently around $48.86%, or 59.44%% of ALGS stock, in the hands of institutional investors. The top three institutional holders of ALGS stocks are: ARMISTICE CAPITAL, LLC with ownership of 7.26 million shares, which is approximately 4.6471%. ECOR1 CAPITAL, LLC, holding 6.39 million shares of the stock with an approximate value of $$2.24 million in ALGS stocks shares; and ECOR1 CAPITAL, LLC, currently with $$2.14 million in ALGS stock with ownership which is approximately 3.9083%.
